Skip to main content
Top
Published in: Diabetologia 7/2009

01-07-2009

Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene–gene interaction

Authors: T. Sparsø, N. Grarup, C. Andreasen, A. Albrechtsen, J. Holmkvist, G. Andersen, T. Jørgensen, K. Borch-Johnsen, A. Sandbæk, T. Lauritzen, S. Madsbad, T. Hansen, O. Pedersen

Published in: Diabetologia | Issue 7/2009

Login to get access

Abstract

Aims/hypothesis

The list of validated type 2 diabetes susceptibility variants has recently been expanded from three to 19. The variants identified are common and have low penetrance in the general population. The aim of the study is to investigate the combined effect of the 19 variants by applying receiver operating characteristics (ROC) to demonstrate the discriminatory value between glucose-tolerant individuals and type 2 diabetes patients in a cross-sectional population of Danes.

Methods

The 19 variants were genotyped in three study populations: the population-based Inter99 study; the ADDITION study; and additional type 2 diabetic patients and glucose-tolerant individuals. The case–control studies involved 4,093 type 2 diabetic patients and 5,302 glucose-tolerant individuals.

Results

Single-variant analyses demonstrated allelic odds ratios ranging from 1.04 (95% CI 0.98–1.11) to 1.33 (95% CI 1.22–1.45). When combining the 19 variants, subgroups with extreme risk profiles showed a threefold difference in the risk of type 2 diabetes (lower 10% carriers with ≤15 risk alleles vs upper 10% carriers with ≥22 risk alleles, OR 2.93 (95% CI 2.38–3.62, p = 1.6 × 10−25). We calculated the area under a ROC curve to estimate the discrimination rate between glucose-tolerant individuals and type 2 diabetes patients based on the 19 variants. We found an area under the ROC curve of 0.60. Two-way gene–gene interaction showed few nominal interaction effects.

Conclusions/interpretation

Combined analysis of the 19 validated variants enables detection of subgroups at substantially increased risk of type 2 diabetes; however, the discrimination between glucose-tolerant and type 2 diabetes individuals is still too inaccurate to achieve clinical value.
Appendix
Available only for authorised users
Literature
1.
go back to reference Altshuler D, Hirschhorn J, Klannemark M et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMedCrossRef Altshuler D, Hirschhorn J, Klannemark M et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMedCrossRef
2.
go back to reference Gloyn A, Weedon M, Owen K et al (2003) Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52:568–572PubMedCrossRef Gloyn A, Weedon M, Owen K et al (2003) Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52:568–572PubMedCrossRef
3.
go back to reference Nielsen E, Hansen L, Carstensen B et al (2003) The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 52:573–577PubMedCrossRef Nielsen E, Hansen L, Carstensen B et al (2003) The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 52:573–577PubMedCrossRef
4.
go back to reference Grant S, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef Grant S, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef
5.
go back to reference Saxena R, Voight B, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef Saxena R, Voight B, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef
6.
go back to reference Scott L, Mohlke K, Bonnycastle L et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345PubMedCrossRef Scott L, Mohlke K, Bonnycastle L et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345PubMedCrossRef
7.
go back to reference Sladek R, Rocheleau G, Rung J et al (2007) A genomewide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885PubMedCrossRef Sladek R, Rocheleau G, Rung J et al (2007) A genomewide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885PubMedCrossRef
8.
go back to reference Steinthorsdottir V, Thorleifsson G, Reynisdottir I et al (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39:770–775PubMedCrossRef Steinthorsdottir V, Thorleifsson G, Reynisdottir I et al (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39:770–775PubMedCrossRef
9.
go back to reference Zeggini E, Scott L, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40:638–645PubMedCrossRef Zeggini E, Scott L, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40:638–645PubMedCrossRef
10.
go back to reference Zeggini E, Weedon M, Lindgren C et al (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336–1341PubMedCrossRef Zeggini E, Weedon M, Lindgren C et al (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336–1341PubMedCrossRef
11.
go back to reference Yasuda K, Miyake K, Horikawa Y et al (2008) Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 40:1092–1097PubMedCrossRef Yasuda K, Miyake K, Horikawa Y et al (2008) Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 40:1092–1097PubMedCrossRef
12.
go back to reference Unoki H, Takahashi A, Kawaguchi T et al (2008) SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 40:1098–1102PubMedCrossRef Unoki H, Takahashi A, Kawaguchi T et al (2008) SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 40:1098–1102PubMedCrossRef
13.
go back to reference Bouatia-Naji N, Bonnefond A, Cavalcanti-Proença C et al (2008) A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41:89–94PubMedCrossRef Bouatia-Naji N, Bonnefond A, Cavalcanti-Proença C et al (2008) A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41:89–94PubMedCrossRef
14.
go back to reference Lyssenko V, Nagorny CL, Erdos MR et al (2008) Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41:82–88PubMedCrossRef Lyssenko V, Nagorny CL, Erdos MR et al (2008) Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41:82–88PubMedCrossRef
15.
go back to reference Prokopenko I, Langenberg C, Florez JC et al (2008) Variants in MTNR1B influence fasting glucose levels. Nat Genet 41:77–81PubMedCrossRef Prokopenko I, Langenberg C, Florez JC et al (2008) Variants in MTNR1B influence fasting glucose levels. Nat Genet 41:77–81PubMedCrossRef
16.
go back to reference Sandhu M, Weedon M, Fawcett K et al (2007) Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 39:951–953PubMedCrossRef Sandhu M, Weedon M, Fawcett K et al (2007) Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 39:951–953PubMedCrossRef
17.
go back to reference Gudmundsson J, Sulem P, Steinthorsdottir V et al (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 39:977–983PubMedCrossRef Gudmundsson J, Sulem P, Steinthorsdottir V et al (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 39:977–983PubMedCrossRef
18.
go back to reference Winckler W, Weedon M, Graham R (2007) Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes 56:685–693PubMedCrossRef Winckler W, Weedon M, Graham R (2007) Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes 56:685–693PubMedCrossRef
19.
go back to reference Florez J, Jablonski K, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250PubMedCrossRef Florez J, Jablonski K, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250PubMedCrossRef
20.
go back to reference Florez J, Jablonski K, McAteer J et al (2008) Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia 51:451–457PubMedCrossRef Florez J, Jablonski K, McAteer J et al (2008) Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia 51:451–457PubMedCrossRef
21.
go back to reference Grarup N, Rose C, Andersson E et al (2007) Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10, 705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 56:3105–3111PubMedCrossRef Grarup N, Rose C, Andersson E et al (2007) Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10, 705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 56:3105–3111PubMedCrossRef
22.
go back to reference Sparsø T, Andersen G, Albrechtsen A et al (2008) Impact of polymorphisms in WFS1 on prediabetic phenotypes in a population-based sample of middleaged people with normal and abnormal glucose regulation. Diabetologia 51:1646–1652PubMedCrossRef Sparsø T, Andersen G, Albrechtsen A et al (2008) Impact of polymorphisms in WFS1 on prediabetic phenotypes in a population-based sample of middleaged people with normal and abnormal glucose regulation. Diabetologia 51:1646–1652PubMedCrossRef
23.
go back to reference Grarup N, Andersen G, Krarup NT et al (2008) Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4, 516 glucose-tolerant middle-aged Danes. Diabetes 57:2534–2540PubMedCrossRef Grarup N, Andersen G, Krarup NT et al (2008) Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4, 516 glucose-tolerant middle-aged Danes. Diabetes 57:2534–2540PubMedCrossRef
24.
go back to reference Frayling T, Timpson N, Weedon M et al (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889–894PubMedCrossRef Frayling T, Timpson N, Weedon M et al (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889–894PubMedCrossRef
25.
go back to reference Dina C, Meyre D, Gallina S et al (2007) Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 39:724–726PubMedCrossRef Dina C, Meyre D, Gallina S et al (2007) Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 39:724–726PubMedCrossRef
26.
go back to reference Ek J, Andersen G, Urhammer SA et al (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176PubMedCrossRef Ek J, Andersen G, Urhammer SA et al (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176PubMedCrossRef
27.
go back to reference Weedon M, McCarthy M, Hitman G (2006) Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med 3:e374PubMedCrossRef Weedon M, McCarthy M, Hitman G (2006) Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med 3:e374PubMedCrossRef
28.
go back to reference Cauchi S, Meyre D, Durand E et al (2008) Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS ONE 5:e2031CrossRef Cauchi S, Meyre D, Durand E et al (2008) Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS ONE 5:e2031CrossRef
29.
go back to reference Lango H, Palmer C, Morris A et al (2008) Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 57:3129–3135PubMedCrossRef Lango H, Palmer C, Morris A et al (2008) Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 57:3129–3135PubMedCrossRef
30.
go back to reference van Hoek M, Dehgan A, Witteman JC et al (2008) Predicting type 2 diabetes based on polymorphisms from genome wide association studies: a population-based study. Diabetes 57:3122–3128PubMedCrossRef van Hoek M, Dehgan A, Witteman JC et al (2008) Predicting type 2 diabetes based on polymorphisms from genome wide association studies: a population-based study. Diabetes 57:3122–3128PubMedCrossRef
31.
go back to reference Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 20:2220–2232CrossRef Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 20:2220–2232CrossRef
32.
go back to reference Meigs JB, Shrader P, Sullivan LM et al (2008) Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 20:2208–2219CrossRef Meigs JB, Shrader P, Sullivan LM et al (2008) Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 20:2208–2219CrossRef
33.
go back to reference Jørgensen T, Borch-Johnsen K, Thomsen T et al (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10:377–386PubMedCrossRef Jørgensen T, Borch-Johnsen K, Thomsen T et al (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10:377–386PubMedCrossRef
34.
go back to reference Lauritzen T, Grin S, Borch-Johnsen K et al (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24:6–11CrossRef Lauritzen T, Grin S, Borch-Johnsen K et al (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24:6–11CrossRef
35.
go back to reference World Health Organization Study Group (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Technical Report Series WHO/NCD/NCS/99.2. WHO, Geneva World Health Organization Study Group (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Technical Report Series WHO/NCD/NCS/99.2. WHO, Geneva
36.
go back to reference Andreasen CH, Stender-Petersen KL, Mogensen MS et al (2008) Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 57:95–101PubMedCrossRef Andreasen CH, Stender-Petersen KL, Mogensen MS et al (2008) Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 57:95–101PubMedCrossRef
37.
go back to reference Helgason A, Pálsson S, Thorleifsson G et al (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218–225PubMedCrossRef Helgason A, Pálsson S, Thorleifsson G et al (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218–225PubMedCrossRef
38.
go back to reference Sparsø T, Bonnefond A, Andersson E et al (2009) The G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. Diabetes (in press) Sparsø T, Bonnefond A, Andersson E et al (2009) The G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. Diabetes (in press)
39.
go back to reference Janssens AC, Moonesinghe R, Yang Q et al (2007) The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases. Genet Med 9:528–535PubMedCrossRef Janssens AC, Moonesinghe R, Yang Q et al (2007) The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases. Genet Med 9:528–535PubMedCrossRef
40.
go back to reference Kryukov GV, Pennacchio LA, Sunyaev SR (2007) Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet 80:727–739PubMedCrossRef Kryukov GV, Pennacchio LA, Sunyaev SR (2007) Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet 80:727–739PubMedCrossRef
Metadata
Title
Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene–gene interaction
Authors
T. Sparsø
N. Grarup
C. Andreasen
A. Albrechtsen
J. Holmkvist
G. Andersen
T. Jørgensen
K. Borch-Johnsen
A. Sandbæk
T. Lauritzen
S. Madsbad
T. Hansen
O. Pedersen
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1362-3

Other articles of this Issue 7/2009

Diabetologia 7/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.